- Abbott to Re-Open Baby Formula Plant on June 4
- Effectiveness of Antiviral Drugs Against Monkeypox Uncertain: Study
- Another Study Finds Kids of Same-Sex Parents Do Just Fine
- Long-Term Heart Inflammation Strikes 1 in 8 Hospitalized COVID Patients
- Use Pot? You May Need More Sedation During Endoscopies
- Colon Cancer Death Rates Are Falling Among the Young — But Only for Whites
- Medical Marijuana May Offer Safe Pain Relief for Cancer Patients
- COVID Can ‘Rebound’ After Treatment With Paxlovid, CDC Says
- AHA News: New Study Looks at Heart Defect Risk in Children of People With Heart Defects
- With Abortion Access Under Threat, Doctors Focus on ‘Contraceptive Counseling’
Parkinson’s Patients at Genetic Risk for Dementia Might Be Identified Sooner

FRIDAY, Sept. 20Blood tests might be able to help identify Parkinson’s disease patients with the greatest risk of developing dementia, a new study suggests.
A genetic mutation called GBA leads to early onset of Parkinson’s and severe mental decline in about 4 percent to 7 percent of Parkinson’s patients. It also alters the way the body metabolizes certain kinds of fats.
Mayo Clinic researchers found that Parkinson’s patients who do not have this genetic mutation have higher levels of these fats in their blood. They also discovered that Parkinson’s patients with high levels of these fats in their blood are more likely to have mental impairment and dementia, according to the study, which was published online Sept. 18 in the journal PLoS One.
Mental impairment is a frequent symptom in Parkinson’s disease and can be even more debilitating for patients and challenging for their caregivers than the characteristic movement issues such as trembling, stiffness, poor coordination and balance problems, the Mayo researchers noted.
They said that early identification of Parkinson’s patients at greatest risk of developing dementia is important for preventing or delaying the start and progression of mental impairment. Changing the levels of these fats in the blood could be one way to do that, the study suggests.
There is also a possibility that assessing the levels of these fats in the blood could help predict who will develop Parkinson’s disease, and research is being conducted in this area.
“There is currently no cure for Parkinson’s, but the earlier we catch it, the better chance we have to fight it,” study first author Michelle Mielke said in a Mayo Clinic news release. “It’s particularly important we find a biomarker and identify it in the preclinical phase of the disease, before the onset even begins.”
More information
The U.S. National Institute of Neurological Disorders and Stroke has more about Parkinson’s disease.
Source: HealthDay